Alternative asset managers CPE and Mirae Asset led a $100m Series B round in JW Therapeutics, a developer of cell-based therapy technologies. The round saw the participation of Chinese state-backed investment firm Oriza Holdings and CR-CP Life Science Fund, a 50-50 joint venture between China Resources Group and Thai conglomerate Charoen Pokphand Group, existing investors including Loyal Valley Capital, Temasek, Sequoia Capital China, ARCH Venture Partners, Juno Therapeutics, a Bristol Myers Squibb company, and WuXi AppTec. "We are very pleased to welcome our new investors and, by working together, we hope to accelerate our product development and serve Chinese Patients,” James Li, JW Therapeutics Co-Founder and CEO.